Private: Fullwidth Portfolio Post

17

Mar2017
New CADTH Processes Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ... Read More

15

Mar2017
CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ... Read More

13

Sep2016
CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ... Read More

26

Aug2016
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ... Read More

26

May2016
Effective immediately, CADTH will be formally engaging with the pan-Canadian Pharmaceutical Alliance (pCPA) and will be including the pCPA office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes. This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed ... Read More

17

May2016
On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions. CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) ... Read More

30

Mar2016
Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective date of the following two CDR procedural revisions: The timing of CDR review team’s responses being provided to the manufacturer, and The revised CDR voluntary withdrawal procedure The revised date for these two ... Read More

30

Mar2016
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert ... Read More

15

Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on  March 11, 2016 for Hospira HealthCare Corporation’s subsequent entry biologic (SEB), INFLECTRA™ (infliximab). According to the CADTH website, Hospira is seeking public reimbursement for Crohn’s disease and Ulcerative Colitis. For those interested in providing ... Read More

10

Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept - the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission. According to the ... Read More